The glucagon-like peptide-1 receptor (GLP-1R) market experienced significant growth in 2023, generating $37.2 billion in ...

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor ...

Predators and prey in the ocean rely on chemical signals for survival, but this vital sensory mode can also be their Achilles ...

Can the upcoming J.P. Morgan Healthcare Conference next week trigger a flurry of biotech M&A deal making activity. Read more ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...

在动荡的市场环境中，市值15.5亿美元的Structure Therapeutics ADR (GPCR)股价已触及52周低点，跌至25.89美元。根据 InvestingPro ...

The TouCAHn trial is an open-label, global, Phase 2 study designed to evaluate the efficacy, safety, and pharmacokinetics of ...

该研究首次发现并命名了一种肠道激素——Cholesin（肠抑脂素），并揭示了Cholesin调控机体 胆固醇 ...

Fintel reports that on January 8, 2025, Stifel initiated coverage of Structure Therapeutics Inc. - Depositary Receipt () ...

Suven Life Sciences surged 9.51% to Rs 138.70 after the firm dosed first subjects in a Phase-1 clinical trial of SUVN-I6107 being conducted in USA under FDA acceptance of investigational new drug (IND ...